Difference between revisions of "Cervarix"
(→Notes) |
(→Notes) |
||
| Line 59: | Line 59: | ||
[[Category:Big Pharma]] | [[Category:Big Pharma]] | ||
| − | |||
| − | |||
Revision as of 13:39, 5 April 2009
Contents
Background
Introduction
Cervarix is a vaccine intended to protect females against the diseases caused by infection with Human Papillomavirus (HPV) types 16 and 18. These diseases include: - cervical cancer(cancer of the cervix i.e. lower part of the uterus or womb), - precancerous cervical lesions(changes in cells of the cervix that have a risk of turning into cancer).
Cervarix will not protect against all types of Human Papillomavirus.HPV types 16 and 18 are responsible for approximately 70% ofcervical cancer cases. When a female is vaccinated with Cervarix, the immune system(the body’s natural defence system) will make antibodies against HPV types 16 and 18.
The Cervarix clinical trial programme
From September 2008, HPV vaccination will be routinely recommended for all girls at 12 to 13 years of age. Initially, there will be a catch-up campaign where girls aged 14 to under 18 years will be offered the vaccine. From September 2009, girls in England, Wales and Northern Ireland aged 16 to 18 will be offered the vaccine. From September 2010, girls aged 15 to 17 will be offered the vaccine.
Biographical Information
History
Current activities
Views
Affiliations
People
Funding
Clients
Publications, Contact, Resources and Notes
Publications
Contact
- Address:
- Phone:
- Email:
- Website:
Resources
http://emc.medicines.org.uk/document.aspx?documentId=20207 Electronic Medicines Compendium
http://www.medicalnewstoday.com/articles/112082.php Medical News Today
